HPV Test Misses Twice the same number of Women Who Develop Cervical Cancer as Cotesting

Overview

• Post By : Kumar Jeetendra


• Source: Quest Diagnostics.


• Date: 17 Jul,2020

A Health Trends research from researchers in Quest Diagnostics, Secaucus, NJ, and the University of Pittsburgh Medical Center demonstrates the human papillomavirus (HPV) screening evaluation is less likely to find cervical cancer and precancer compared to cotesting, a procedure that combines HPV and Pap (Papanicolaou evaluation by liquid-based cytology) testing with the exact same specimen¹

The study is the largest so far to estimate the operation of all guideline-recommended cervical cancer screening approaches at a varied population of American girls in real-world care preferences. It shows stark differences in the operation of the many suggested methods in detecting cancer and precancers in women 30 decades old and older.

The Health Trends study analyzed sensitivity levels of HPV alone, Pap independently, also cotesting in discovering cancer and precancer of the cervix in almost 19 million deidentified cotest effects achieved by Quest Diagnostics on behalf of 13.6 million girls in america by 2010 to 2018. Of those circumstances, 1,259 were diagnosed with cervical cancertwice the amount of cancer cases as the next biggest study²

“It should put to rest any thought that HPV alone accomplishes the identical pub for cancer screening”

“Since many cervical cancers grow in the absence of standard screening, making sure women have access to the most dependable screening procedure, cotesting, when they’re screened is a vital step in reducing mortality from the disease.”

Among the key findings

1. HPV and Pap testing alone fails to detect twice as many women who develop cervical cancer as cotesting. Of 1,615 cotests taken at any time prior to a cancer diagnosis, 86.9% were positive by cotesting, a non detection rate (also known as false negative) of about 13.1%. By comparison, Pap and HPV testing alone had non detection rates nearly twice as high: Pap at 26.4% and HPV at 28.4%.
2. Cotesting detected significantly more women who developed biopsy-confirmed adenocarcinomas, a typically aggressive form of cervical cancer, identifying 82.3% of this cancer compared to only 61.2% by HPV and 59.7% by Pap.
3. HPV test fails to identify one in five women who develop cancer when performed within a year of cancer diagnosis. Among women screened within one year of a cancer diagnosis, the non-detection rate for HPV testing alone was 22.5%, nearly 1.5 times higher than Pap (14.9%) and four times higher than cotesting (5.9%).
4. Cotesting detected more women who developed biopsy-confirmed precancers than HPV or Pap alone, identifying 95.6% of these precancers, compared to 92.6% by HPV and 77.9% by Pap.

“For girls who might not be screened in any way, there’s absolutely no question which cytology or HPV main are helpful testing technologies,” says Damian P. Alagia, III, MD, senior medical director of lady’s wellbeing for Quest Diagnostics. “Yet that shouldn’t obscure the reality that cotesting is basically the better screening choice for girls and is widely accessible in the USA.”

For more information, visit Quest Diagnostics.

References

1. Austin RM, Onisko A, Zhao C. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV cotesting. Am J Clin Pathol. 2018;150:385-392. doi.org/10.1093/ajcp/aqy114.
2. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Woman’s Health.2012;21(10):1031-1037.doi: 10.1089/jwh.2011.3385.